Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioSeed-C versus chondrotissue for focal femoral knee cartilage defects
2011-003594-28Phase 3Completed
- Sponsor
- Biotissue Technologies
- Start
- Nov 2011
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BioSeed-C in Focal femoral cartilage defect of the knee (FFCD) and cartilage defect (2 arms), sponsored by Biotissue Technologies. Primary endpoints: Primary efficacy endpoint and Primary endpoint as listed in registry. Started Nov 2011; status: completed.
02
Drugs
BioSeed-C
03
Conditions
Focal femoral cartilage defect of the knee (FFCD)cartilage defect
Beyond the preview
Go deeper on 2011-003594-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003594-28.